BUD — Budget/Appropriations
FY 2025 Budget Resolution - Pharmaceutical Related Provisions
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
1st Quarter - Report · 2026
- Filing UUID
3b416d20-48aa-4ead-8648-66c1a5de2a6b- Type
Q1— 1st Quarter - Report- Period
- first_quarter
- Year
- 2026
- Posted
- 2026-04-20 15:03:24
- Income (reported)
- —
- Expenses (reported)
- $1,410,000
- Expenses method
- A
- Filing document
- Open on lda.senate.gov
Registrant (lobbying firm)
TAKEDA PHARMACEUTICALS AMERICA, INC.
Pharmaceutical Company
- Contact
- ANDREW KAPLAN
- Phone
- +1 202-649-4004
- Address
- zip:20024, city:Washington, state:DC, street:670 Maine Ave SW Suite 210
Client
TAKEDA PHARMACEUTICALS AMERICA INC
- State
- DC
- Country
- US
- Government-entity client
- false
- Effective date
- 2009-11-01
Issues lobbied + lobbyists (6)
MMM — Medicare/Medicaid
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAX — Taxation/Internal Revenue Code
Administration's Global Tax Proposal General issues around 2026 Reconciliation/Inbound Concerns
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES
TRD — Trade (domestic/foreign)
General intellectual property policy issues Issues related to proposed Tariffs - all pharmaceutical related provisions
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
DEF — Defense
Discussions around Supply Chain implications
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE